{"id":7263,"date":"2023-07-12T11:00:50","date_gmt":"2023-07-12T03:00:50","guid":{"rendered":"https:\/\/www.9-design.net\/?p=7263"},"modified":"2023-07-17T11:02:20","modified_gmt":"2023-07-17T03:02:20","slug":"eisai-to-present-the-latest-alzheimers-disease-pipeline-and-research-including-lecanemab-and-anti-mtbr-tau-antibody-e2814-at-the-alzheimers-association-international-conference-aa","status":"publish","type":"post","link":"https:\/\/www.9-design.net\/en\/2023\/07\/12\/eisai-to-present-the-latest-alzheimers-disease-pipeline-and-research-including-lecanemab-and-anti-mtbr-tau-antibody-e2814-at-the-alzheimers-association-international-conference-aa\/","title":{"rendered":"EISAI TO PRESENT THE LATEST ALZHEIMER\u2019S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER\u2019S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023"},"content":{"rendered":"<p>Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that the company will present the latest findings on its Alzheimer\u2019s disease (AD) pipeline and research, including Eisai\u2019s anti-amyloid beta (A\u03b2) protofibril* antibody for the treatment of Alzheimer\u2019s disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI<sup>\u00ae<\/sup>), and the company\u2019s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer\u2019s Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023. Eisai will present data and research in eight oral and 19 poster presentations at the meeting. Two of the AAIC oral presentations will be presented as posters at the Alzheimer\u2019s Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.<\/p>\n<p>\u201cAt AAIC 2023 Eisai will present the latest data on lecanemab, an anti-A\u03b2 protofibril antibody, that recently received traditional approval in the U.S. for patients with mild cognitive impairment (MCI) due to AD and mild AD. Leqembi was studied in a broad population, which included a mix of racial and ethnic groups and patients with common comorbid conditions and concomitant medications.\u201d Additionally, Eisai will present important new data on E2814, an anti-MTBR tau antibody, which is currently in Phase II\/III clinical trials with the Dominantly Inherited Alzheimer\u2019s Network Trials Unit at Washington University St. Louis,\u201d said Michael Irizarry, M.D., Deputy Chief Clinical Officer and Senior Vice President of Clinical Research, Alzheimer\u2019s Disease and Brain Health, Eisai Inc. \u201cAs part of Eisai\u2019s commitment to transparency and our <em>human health care (hhc)<\/em> and ecosystem mission, we will continue to present and publish data and information about our AD pipeline and research.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-7257 aligncenter\" src=\"https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z.png\" alt=\"\" width=\"966\" height=\"3688\" srcset=\"https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z.png 966w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-157x600.png 157w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-268x1024.png 268w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-768x2932.png 768w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-402x1536.png 402w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-393x1500.png 393w, https:\/\/www.9-design.net\/wordpress\/wp-content\/uploads\/2023\/07\/\u706b\u72d0\u622a\u56fe_2023-07-17T02-51-40.072Z-185x705.png 185w\" sizes=\"(max-width: 966px) 100vw, 966px\" \/><\/p>\n<p>Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.<\/p>\n<p>This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.<\/p>\n<p>&nbsp;<\/p>\n<p>MEDIA CONTACTS:<br \/>\nEisai Co., Ltd.<br \/>\nPublic Relations Department<br \/>\nTEL: +81 (0)3-3817-5120<\/p>\n<p>Eisai Inc. (U.S.)<br \/>\nLibby Holman<br \/>\n+ 1-201-753-1945<br \/>\nLibby_Holman@Eisai.com<\/p>\n<p>Eisai Europe, Ltd.<br \/>\n(UK, Europe, Australia, New Zealand and Russia)<br \/>\nEMEA Communications Department<br \/>\n+44 (0) 786 601 1272<br \/>\nEMEA-comms@eisai.net<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that the company will present the latest findings on its Alzheimer\u2019s disease (AD) pipeline and research, including Eisai\u2019s anti-amyloid beta (A\u03b2) protofibril* antibody for the treatment of Alzheimer\u2019s disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI\u00ae), and the company\u2019s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer\u2019s Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023. Eisai will present data and research in eight oral and 19 poster presentations at the meeting. Two of the AAIC oral presentations will be presented as posters at the Alzheimer\u2019s Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"_links":{"self":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7263"}],"collection":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/comments?post=7263"}],"version-history":[{"count":3,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7263\/revisions"}],"predecessor-version":[{"id":7265,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7263\/revisions\/7265"}],"wp:attachment":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/media?parent=7263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/categories?post=7263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/tags?post=7263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<a href="http://www.9-design.net/">久久人人97超碰超国产,天天摸夜夜添夜夜无码,久久精品人人槡人妻人人玩,97碰碰碰人妻无码视频</a>
<script>
(function(){
    var bp = document.createElement('script');
    var curProtocol = window.location.protocol.split(':')[0];
    if (curProtocol === 'https') {
        bp.src = 'https://zz.bdstatic.com/linksubmit/push.js';
    }
    else {
        bp.src = 'http://push.zhanzhang.baidu.com/push.js';
    }
    var s = document.getElementsByTagName("script")[0];
    s.parentNode.insertBefore(bp, s);
})();
</script>
</body>